BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q2 2025 vs. Q1 2025
How the institutions holding BIO-TECHNE Corp changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 578 | 4 | 556 | −18 |
| Shares | 162.4M | 44.1K | 158.6M | −3.70M (−2.3%) |
| Value | $9.52B | $2.59M | $8.16B | −$1.35B (−14.2%) |
4 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (82)
Institutions that held BIO-TECHNE Corp at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (100)
Institutions that held BIO-TECHNE Corp at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (4)
Institutions that held BIO-TECHNE Corp at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Credit Agricole S A | 15,113 | $886.1K |
| Rakuten Investment Management, Inc. | 14,471 | $849.9K |
| Mizuho Securities USA LLC | 12,658 | $742.1K |
| Lindbrook Capital, LLC | 1,831 | $107.4K |